Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin in JAK2V617F-Positive Myeloproliferative Neoplasms
2020-004652-15Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Apr 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban, rivaroxaban and aspirin in myeloproliferative disorder (MPD), polycythemia vera (PV), thrombocythemia and 1 more (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Started Apr 2021; status: active.
02
Drugs
apixabanrivaroxabanaspirin
03
Conditions
myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiaprefibrotic primary myelofibrosis (pre-PMF)
Beyond the preview
Go deeper on 2020-004652-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004652-15.